ClinVar Miner

Submissions for variant NM_000321.3(RB1):c.2326-2A>G

dbSNP: rs1949432057
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001057987 SCV001222519 pathogenic Retinoblastoma 2019-01-09 criteria provided, single submitter clinical testing Experimental studies have shown that this variant disrupts mRNA splicing (PMID:18449911). For these reasons, this variant has been classified as Pathogenic. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in RB1 are known to be pathogenic (PMID: 17096365). This variant has been observed individuals affected with retinoblastoma (PMID: 18449911, Invitae). This variant is also known as IVS22–2A>G in the literature. This variant is not present in population databases (ExAC no frequency). This sequence change affects an acceptor splice site in intron 22 of the RB1 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.